source
- ‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drugA new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.
- Apnimed aspires for up to $160M IPO as sleep apnea pill launch nearsApnimed has detailed its plans for an initial public offering, with the biotech intending to raise as much as $160 million to fund the launch of its sleep apnea pill.